LymphoVista HL Assay results presented at ASH 2024 Annual Meeting
Liqomics, a leading innovator in cancer diagnostics, is thrilled to announce the presentation of data on the LymphoVista HL assay at the 2024 Annual Meeting of the American Society of Hematology (ASH) in San Diego. This cutting-edge circulating tumor DNA (ctDNA) assay is tailored for minimal residual disease (MRD) monitoring and genotyping in Hodgkin Lymphoma (HL), setting new standards in precision oncology in this disease.
The LymphoVista HL assay demonstrated outstanding sensitivity and specificity in its technical and clinical validation. Utilizing highly sensitive ctDNA sequencing, the assay enables detection of MRD at levels as low as few molecules per million, providing insights into treatment response and relapse risk. Clinical data from 72 HL patients treated within the HD21 trial (Borchmann et al., Lancet, 2024) underscore its prognostic value. patients who were MRD-negative after two cycles of therapy achieved a four-year progression-free survival (PFS) rate of 95.3%. In contrast, MRD-positive patients showed a significantly higher relapse risk with a four-year PFS of 72.2%, (hazard ratio (HR) 6.9 (95%-CI: 4.5-10.6), p < 0.0001). The median follow-up was 50 months. In subgroup analyses, MRD-2 remained prognostic for patients treated with BrECADD (4-year PFS MRD-2 positive vs. negative: 97.4 vs. 52.0%, HR 25.4 (95%-CI: 12.5 – 51.7), p < 0.0001), for patients treated with eBEACOPP (4-year PFS MRD-2 positive vs. negative: 92.4 vs. 80.0%, HR 2.8 (95%-CI: 1.6 – 4.9), p = 0.0002), as well as for patients with positive PET-2 (4-year PFS MRD-2 positive vs. negative: 87.7 vs. 63.7%, HR 3.5 (95%-CI: 2.0 – 6.0), p < 0.0001), and patients with negative PET-2 (4-year PFS MRD-2 positive vs. negative: 98.4 vs. 81.4%, HR 13.2 (95%-CI: 6.1 – 28.4), p < 0.0001).
LymphoVista HL empowers the implementation of MRD-guided treatment strategies, paving the way for precision medicine in Hodgkin lymphoma. By identifying genomic variations and tracking them with unprecedented accuracy, the assay allows monitoring of treatment efficacy.
ASH Presentation Details
The LymphoVista HL abstract was presented during a poster session on Monday, December 9th 2024. For full details on the LymphoVista HL data presented at the meeting, visit the ASH 2024 Abstract.
About Liqomics
Liqomics GmbH specializes in the development of high-sensitivity cell-free DNA assays, with a focus on enabling precise monitoring and personalized treatments for cancer patients. Headquartered in Cologne, Germany, Liqomics provides innovative diagnostics for lymphomas and beyond. Follow our page on Linkedin!
